Development of a rapid method for determining the susceptibility of Mycobacterium tuberculosis to isoniazid using the Gen-Probe DNA Hybridization System.

Antimicrobial Agents and Chemotherapy
D E KawaR F Schell

Abstract

A rapid test was developed for determining the susceptibility of Mycobacterium tuberculosis to isoniazid by using nucleic acid hybridization. The method was based on quantification of total mycobacterial rRNA hybridized to a 125I-labeled DNA probe in the absence and presence of various concentrations of isoniazid. The radioactive hybridized complex was isolated by adsorption to hydroxyapatite crystals and measured in a gamma counter. The susceptibilities of four reference strains and 20 clinical isolates were compared by the Gen-Probe DNA Hybridization System and the critical concentration method. Overall agreement between the two methods was excellent. Results were obtained with the DNA probe after 3 to 5 days of incubation instead of the 14 to 21 days required for the critical concentration method. These findings indicate that susceptibility testing of M. tuberculosis by nucleic acid hybridization has merit for the clinical laboratory. Additional studies are needed to determine the efficacy of the DNA probe method for determining the susceptibility of M. tuberculosis to other antimycobacterial agents and its correlation with clinically significant levels of resistance.

References

Aug 1, 1987·Journal of Clinical Microbiology·T A DrakeD A Bruckner
Aug 1, 1988·Antimicrobial Agents and Chemotherapy·L E NilssonS Anséhn
Sep 1, 1988·Journal of Clinical Microbiology·A M VannierP R Murray
Jun 1, 1967·Journal of General Microbiology·J W Wimpenny

❮ Previous
Next ❯

Citations

Jan 1, 1992·Journal of Medical and Veterinary Mycology : Bi-monthly Publication of the International Society for Human and Animal Mycology·G M ScalaroneK Pusater
Apr 12, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D J DeCosterR F Schell
Nov 5, 2010·Veterinary Immunology and Immunopathology·John P Bannantine, Adel M Talaat
May 18, 2006·Journal of Microbiological Methods·Beth A FredricksRonald F Schell
Oct 1, 1991·Clinical Microbiology Reviews·D F Welch
Oct 8, 1997·Journal of Clinical Microbiology·N Martin-CasabonaL Arcalis
Jan 16, 1999·Journal of Clinical Microbiology·T J HellyerK D Eisenach
May 1, 1995·Journal of Clinical Microbiology·M A NordenR F Schell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.